Masimo

Masimo Corp. is a medical technology company, which develops, manufactures and markets noninvasive patient monitoring technologies, medical devices and sensors. Its products include continuous monitors, patient-worn monitors, hospital automation connectivity, capnography & gas, data download & analytics and sensors & accessories. The company was founded by Joe E. Kiani in May 1989 and is headquartered in Irvine, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Masimo reports robust Q4 earnings, eyes new product launches

Masimo's Q4 2022 earnings call highlighted strong financial performance, growth projections for 2023, and a focus on innovation and regulatory advancements. While facing challenges like supply chain issues and legal disputes, the company remains optimistic about opportunities in new product launches and revenue growth drivers. Overall, Masimo is poised for continued success in the healthcare market.

Masimo reports robust Q1 earnings, navigates challenges with strategic focus

Masimo's Q1 performance reflects strong revenue growth and product innovation, underpinned by a focus on healthcare technology and wearables for chronic illness monitoring.
While facing challenges such as litigation costs and regulatory clearances, Masimo maintains its financial guidance for 2023, signaling stability and strategic resilience.
The company's emphasis on new product launches, diverse pricing strategies, and global market expansion positions it well to capitalize on opportunities in the healthcare sector.

Masimo faces revenue challenges in Q2 but eyes rebound

Masimo's Q2 performance was impacted by revenue challenges in Healthcare and non-healthcare segments, leading to a revised revenue guidance for 2023.
The company is focusing on expense control measures, new product opportunities, and pricing discipline to drive profitability and rebound in business segments.
Despite challenges, Masimo remains optimistic about market opportunities in telehealth, consumer health, and the potential for revenue growth from products like Stork.
Ongoing litigation with Apple and uncertainties in customer order patterns pose challenges, but the company is implementing strategies to address these issues.

Masimo reports solid Q3 earnings, eyes growth in consumer health

Masimo's Q3 performance showcased strong revenue but challenges in sensor utilization recovery. The company's innovative products and expansion into consumer health signal growth potential. Addressing challenges in revenue guidance and market competition will be key focus areas for future success.

Masimo reports robust Q4 earnings, legal wins and growth opportunities

Masimo's strong Q4 performance and strategic focus on healthcare and hearables/wearables growth position the company well for 2024.
Legal victories in Apple litigation and FDA clearances for innovative products underscore Masimo's commitment to innovation and protecting its intellectual property.
While facing challenges in legal proceedings and product clearances, Masimo has opportunities to drive revenue growth through product innovation and market expansion.

Masimo reports strong Q1 earnings, plans consumer business separation

Masimo's Q1 2024 Earnings Call showcased robust financial performance, strategic revenue diversification, and plans for enhancing shareholder value through potential separation of the consumer business. While facing challenges in operational transitions and financial metrics scrutiny, the company is well-positioned for growth and value creation.

Masimo reports robust Q3 performance and outlines growth opportunities

Masimo's Q3 2024 earnings call showcased strong financial performance, strategic reviews, and growth initiatives. While facing challenges in margin progression and potential disruptions, the company is poised for growth with opportunities in revenue expansion and margin improvement.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Masimo Corp. is a global technology company, which engages in the development, manufacture, and marketing of patient monitoring technologies, and automation and connectivity solutions. Its products include remote patient monitoring, connectivity, and hospital automation solutions, including Masimo Patient SafetyNet, Masimo Patient SafetyNet Surveillance, Masimo SafetyNet, Masimo SafetyNet-Open, Replica, Iris, MyView, UniView, Uniview: 60, Trace, Masimo Sleep, Centroid, and Bridge. The company was founded by Joe E. Kiani in May 1989 and is headquartered in Irvine, CA.

Masimo Chief Operating Officer Bilal Muhsin has told the board he would resign if activist investor Politan Capital Management takes control of the company and CEO Joe Kiani is removed, according to a regulatory filing.

Masimo COO Muhsin to resign if activist investor Politan takes control

NEW YORK, June 30, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Masimo Corporation (“Masimo” or the “Company”) (NASDAQ: MASI).   Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Masimo Corporation – MASI

Masimo (MASI) collaborates with Cleveland Clinic to boost patient care by combining its Hospital Automation platform with the latter's central patient monitoring platforms.

Masimo (MASI), Cleveland Clinic Unite to Enhance Patient Care

Hologic

Veracyte

Deteriorating geopolitical situation and supply bottlenecks mar the prospects of the Zacks Medical Instruments industry. Yet, HOLX, MASI and VCYT are worth buying based on strategic developments and fundamentals.

3 Medical Instruments Picks to Navigate Industry Challenges

IRVINE, Calif. & CLEVELAND--(BUSINESS WIRE)--Masimo and Cleveland Clinic are launching a new partnership centered around hospital-based remote patient monitoring, including TeleCritical Care.

Masimo and Cleveland Clinic Collaborate to Improve Hospital Remote Care

NEW YORK, NY / ACCESSWIRE / June 26, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Masimo Corporation ("Masimo" or the "Company") (NASDAQ:MASI). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Masimo Corporation - MASI

IRVINE, Calif.--(BUSINESS WIRE)--Masimo Corporation (“Masimo” or the “Company”) (Nasdaq: MASI) today filed an investor presentation with the U.S. Securities and Exchange Commission in connection with its Annual Meeting of Stockholders to be held on July 25, 2024. The presentation lays out in detail: The Company's robust track record of innovation, led by Masimo Founder, Chairman and CEO Joe Kiani, that supports Masimo's longstanding valuation premium to industry peers; Masimo's strategic initia.

Masimo Files Investor Presentation Highlighting Innovation-Driven Value, Strategic Initiatives to Deliver Robust Growth and Margin Expansion and Risks of Ceding Control to Politan

NEW YORK--(BUSINESS WIRE)--Politan Capital Management (together with its affiliates, “Politan”), an 8.9% shareholder of Masimo Corporation (“Masimo” or the “Company”) (NASDAQ: MASI), today sent a letter to the Company's shareholders outlining why a majority of truly independent directors are urgently needed in the Masimo boardroom. Politan also released a detailed investor presentation making the case for change and why independent nominees – Darlene Solomon, former Chief Technology Officer of.

Politan Details Why a Truly Independent Board is Urgently Needed at Masimo in Order to Protect Shareholder Value and Realize the Company's Full Potential

Masimo activist Politan laid out its renewed case for change in a push to win two more board seats at the medical device company. Politan seeks to oust CEO Joe Kiani from the board and says the company can deliver $10 billion in shareholder value with the right governance and oversight.

Masimo activist Politan presents 'last chance' for shareholders to force change at med-tech company

IRVINE, Calif., June 24, 2024 /PRNewswire/ -- Knobbe Martens secured another victory for Masimo Corporation (NASDAQ: MASI) with the successful dismissal with prejudice of a patent infringement lawsuit filed by Wrist SP Biotech, a non-practicing entity (NPE).

In Another Win for Masimo, Knobbe Martens Secures Dismissal of Infringement Lawsuit

NEW YORK, June 23, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Masimo Corporation (NASDAQ: MASI) resulting from allegations that Masimo may have issued materially misleading business information to the investing public.

ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Masimo Corporation Investors to Inquire About Securities Class Action Investigation – MASI

IRVINE, Calif.--(BUSINESS WIRE)--Masimo (NASDAQ: MASI) today issued the following statement to set the record straight regarding Politan's “Background of the Solicitation” section of its proxy statement issued in connection with Masimo's upcoming Annual Meeting of Stockholders. Masimo strongly believes Politan is providing investors with inaccurate and incomplete information, as Masimo Founder, Chairman and CEO Joe Kiani noted during the Goldman Sachs Global Healthcare Conference on June 12, 20.

Masimo Provides Facts in Response to Politan's False Narrative

NEW YORK, June 19, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Masimo Corporation (NASDAQ: MASI) resulting from allegations that Masimo may have issued materially misleading business information to the investing public.

Masimo Corporation Announcement: If You Have Suffered Losses in Masimo Corporation (NASDAQ: MASI), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

IRVINE, Calif.--(BUSINESS WIRE)--Members of the Masimo Corporation (“Masimo” or the “Company”) (NASDAQ: MASI) Board of Directors today issued a letter to stockholders in connection with its definitive proxy materials filed on June 17, 2024, and the Company's Annual Meeting of Stockholders to be held on July 25, 2024. The letter highlights what in our view are the significant risks to the value of Masimo if control of the Board is ceded to Politan Capital Management (“Politan”), which we believe.

Masimo Board of Directors Files Definitive Proxy and Issues Letter to Stockholders

NEW YORK, June 15, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Masimo Corporation (NASDAQ: MASI) resulting from allegations that Masimo may have issued materially misleading business information to the investing public.

ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Masimo Corporation Investors to Inquire About Securities Class Action Investigation – MASI

NEW YORK, June 13, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Masimo Corporation (“Masimo” or the “Company”) (NASDAQ: MASI).   Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com  or 646-581-9980, ext. 7980.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Masimo Corporation - MASI

NEW YORK , June 11, 2024 /PRNewswire/ -- WHY: June 11, 2024. Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Masimo Corporation (NASDAQ: MASI) resulting from allegations that Masimo may have issued materially misleading business information to the investing public.

Rosen Law Firm Urges Masimo Corporation (MASI) Stockholders with Large Losses to Contact the Firm for Information About Their Rights

NEW YORK, June 10, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Masimo Corporation (NASDAQ: MASI) resulting from allegations that Masimo may have issued materially misleading business information to the investing public.

ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Masimo Corporation Investors to Inquire About Securities Class Action Investigation – MASI

NEW YORK, June 06, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Masimo Corporation (NASDAQ: MASI) resulting from allegations that Masimo may have issued materially misleading business information to the investing public.

MASI INVESTOR NOTICE: ROSEN, A TOP RANKED LAW FIRM, Encourages Masimo Corporation Investors to Inquire About Securities Class Action Investigation – MASI

IRVINE, Calif.--(BUSINESS WIRE)--Masimo (NASDAQ: MASI) today announced that its management will participate in the Goldman Sachs 45th Annual Global Healthcare Conference on Wednesday, June 12, 2024 at 8:00 a.m. Eastern Time. A live webcast of the presentation will be available on the Masimo website at www.masimo.com. A replay of the webcast will be available following the live presentation. About Masimo Masimo (Nasdaq: MASI) is a global technology company that develops and produces a wide array.

Masimo to Present in Goldman Sachs 45th Annual Global Healthcare Conference

FutureFuel

NEW YORK, June 05, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Masimo Corporation (NASDAQ: MASI), and FutureFuel Corp. (NYSE: FF). Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices. Additional information about each case can be found at the link provided.

Bragar Eagel & Squire, P.C. Is Investigating Masimo, and FutureFuel and Encourages Investors to Contact the Firm

Bank of America

Gap Inc

BAC, GPS and MASI made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on June 5, 2024.

Best Momentum Stocks to Buy for June 5th

IRVINE, Calif.--(BUSINESS WIRE)--Masimo is partnering with Mobilize Recovery, which is dedicated to ending the addiction and overdose crisis, by sponsoring its 2024 bus tour.

Masimo Joins Forces with the Mobilize Recovery 2024 Bus Tour

NEW YORK , June 4, 2024 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Masimo Corporation (NASDAQ: MASI) resulting from allegations that Masimo may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Masimo securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

ROSEN, LEADING INVESTOR COUNSEL, Encourages Masimo Corporation Investors to Inquire About Securities Class Action Investigation - MASI

NEW YORK--(BUSINESS WIRE)--Politan Capital Management (together with its affiliates, “Politan”), an 8.9% shareholder of Masimo Corporation (“Masimo” or the “Company”) (NASDAQ: MASI), today announced that it has filed a preliminary proxy statement with the U.S. Securities and Exchange Commission in connection with its nomination of two independent candidates for election to the Masimo Board of Directors (the “Board”) at the upcoming 2024 Annual Meeting of Stockholders (the “Annual Meeting”), whi.

News for Masimo Stock (MASI)